Get the Stockscreener App
14.75
9.42%
1.27
Eyepoint Inc stock is traded at $14.75, with a volume of 2.51M.
It is up +9.42% in the last 24 hours and up +7.43% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$13.48
Open:
$13.53
24h Volume:
2.51M
Relative Volume:
1.76
Market Cap:
$1.27B
Revenue:
$7.62M
Net Income/Loss:
$-271.60M
P/E Ratio:
-4.2121
EPS:
-3.5018
Net Cash Flow:
$-271.54M
1W Performance:
+6.19%
1M Performance:
+7.43%
6M Performance:
+13.99%
1Y Performance:
+35.94%
1-Day Range:
$13.40
$14.76
1-Week Range:
$12.37
$14.76
52-Week Range:
$9.65
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.75 | 1.17B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
EyePoint Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Cormorant Asset Management (EYPT) reports 7,000,000 EyePoint shares in 13G/A - Stock Titan
Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System - MarketBeat
EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing - simplywall.st
Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals, Inc. (EYPT) options chain - Yahoo Finance UK
Adage Capital discloses 4.79M-share EyePoint, Inc. (EYPT) position in Schedule 13G - Stock Titan
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - Kalkine
EyePoint, Inc (NASDAQ: EYPT) Share Price, EYPT Stock News, EYPT Share Price & Updates - kalkine.ca
Eyepoint Pharma earnings missed by $0.15, revenue topped estimates - Investing.com Nigeria
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Negative Outlook for EYPT Earnings - MarketBeat
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
EyePoint Pharma nears key Phase III data for DU... - pluang.com
EyePoint: Phase 3 Design Creates A More Valuable Durability Story (NASDAQ:EYPT) - Seeking Alpha
EyePoint Is Maintained at Buy by Chardan Capital - Moomoo
EYPT Maintained by Chardan Capital -- Price Target Remains at $6 - GuruFocus
Eyepoint Pharmaceuticals' (EYPT) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking a 218% Potential Upside in the Biotech Sector - directorstalkinterviews.com
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results - MarketBeat
EYPT Maintained by Cantor Fitzgerald -- Price Target Raised to $55 - GuruFocus
EyePoint, Inc. Stock 12‑Month Price Target Cut to $40.86, Implies 234% Upside - TradingView
EYPT Maintains by HC Wainwright & Co. -- Price Target Lowered to $27 - GuruFocus
HC Wainwright Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald - MarketBeat
A Quick Look at Today's Ratings for EyePoint(EYPT.US), With a Forecast Between $20 to $55 - Moomoo
Is EyePoint Inc (EYPT) Worth the Price After Q2 Earnings Miss? G - GuruFocus
EyePoint, Inc. 2Q 2026: Revenue $507K, Net loss $(94.47M), EPS $(1.09) — 10-Q Summary - TradingView
[10-Q] EyePoint, Inc. Quarterly Earnings Report - Stock Titan
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
EyePoint Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, vs. FactSet Est of $390,000 - marketscreener.com
EYPT Looks 1591.3% Overvalued on GF Value™ - GuruFocus
EyePoint: Q2 Earnings Snapshot - marketscreener.com
EyePoint Pharmaceuticals Q2 revenue drops on lower license income - TradingView
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Q2 revenue falls to $0.5 million as Phase 3 data nears - quiverquant.com
EYPT: Q2 2026 featured higher R&D costs and a $94.5M net loss as DURAVYU Phase 3 trials progressed - TradingView
EyePoint reports Q2 loss of $94.5M, cash and investments $180M; LUGANO topline due Aug 2026 - TradingView
Earnings Flash (EYPT) EyePoint, Inc. Reports Q2 Revenue $507,000, Vs. FactSet Est of $390,000 - Moomoo
EyePoint, Inc. (Nasdaq: EYPT) widens loss as DURAVYU Phase 3 trials near key data - Stock Titan
Ahead‑of‑Schedule DME Trial Enrollment Could Be A Game Changer For EyePoint (EYPT) - Sahm
Eyepoint Pharma earnings on deck ahead of pivotal trial data - Investing.com
Eyepoint Pharma earnings on deck ahead of pivotal trial data By Investing.com - Investing.com South Africa
EYPT: DURAVYU advances as a potential first-in-class, long-acting TKI for major retinal diseases - TradingView
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.3%Here's Why - MarketBeat
Janus Henderson Group PLC Grows Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT - MarketBeat
Price to earnings forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Vanguard Capital Management (EYPT) discloses 4.22M-share, 5.03% holding in EyePoint - Stock Titan
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):